Gross Profit Comparison: AbbVie Inc. and Bio-Techne Corporation Trends

Biotech Giants' Profit Trends: AbbVie vs. Bio-Techne

__timestampAbbVie Inc.Bio-Techne Corporation
Wednesday, January 1, 201415534000000251411000
Thursday, January 1, 201518359000000307277000
Friday, January 1, 201619805000000336659000
Sunday, January 1, 201721176000000374541000
Monday, January 1, 201825035000000432143000
Tuesday, January 1, 201925827000000473491000
Wednesday, January 1, 202030417000000483194000
Friday, January 1, 202138751000000632850000
Saturday, January 1, 202240640000000756496000
Sunday, January 1, 202333903000000769815000
Monday, January 1, 202439430000000769725000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotech Giants: AbbVie Inc. vs. Bio-Techne Corporation

In the ever-evolving landscape of biotechnology, the financial performance of industry leaders offers a window into their strategic prowess. From 2014 to 2023, AbbVie Inc. and Bio-Techne Corporation have showcased contrasting trajectories in gross profit. AbbVie, a titan in the pharmaceutical world, saw its gross profit soar by approximately 118% from 2014 to 2022, peaking in 2022 before a slight dip in 2023. Meanwhile, Bio-Techne, a key player in the life sciences sector, experienced a steady growth of around 206% over the same period, reflecting its robust expansion strategy.

While AbbVie's profits are significantly higher, Bio-Techne's consistent growth underscores its resilience and potential in the biotech arena. The absence of data for AbbVie in 2024 leaves room for speculation, highlighting the dynamic nature of the industry and the importance of strategic adaptability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025